Treatment of recurrent glioblastoma: Can local delivery of mitoxantrone improve survival?

Amerigo Boiardi, Antonio Silvani, Marica Eoli, Elena Lamperti, Andrea Salmaggi, Paola Gaviani, Anna Fiumani, Andrea Botturi, Chiara Falcone, Alessandra Solari, Graziella Filippini, Francesco Meco, Giovanni Broggi

Research output: Contribution to journalArticle

Abstract

In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1-5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43%, respectively, with a median survival time (mST) of 5 months (range 4-6) and 25% of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1%, respectively, with a mST of 8 months (range 6-10) and 25% of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7%, respectively, with a mST of 11 months (range 9-13) and 25% of pts alive at 18 months (A vs. B vs. C, log-rank P <0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36% the risk of death (HR = 0.64; 0.460-0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50% (HR = 0.50; 0.38-0.68).

Original languageEnglish
Pages (from-to)105-113
Number of pages9
JournalJournal of Neuro-Oncology
Volume88
Issue number1
DOIs
Publication statusPublished - May 2008

Fingerprint

Mitoxantrone
Glioblastoma
temozolomide
Survival
Disease-Free Survival
Therapeutics
Recurrence
Survivors
Neoplasms
Proportional Hazards Models
Drug Therapy

Keywords

  • Glioblastoma
  • Locoregional chemotherapy
  • Mitoxantrone
  • Ommaya reservoir
  • Rickam reservoir

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Treatment of recurrent glioblastoma : Can local delivery of mitoxantrone improve survival? / Boiardi, Amerigo; Silvani, Antonio; Eoli, Marica; Lamperti, Elena; Salmaggi, Andrea; Gaviani, Paola; Fiumani, Anna; Botturi, Andrea; Falcone, Chiara; Solari, Alessandra; Filippini, Graziella; Meco, Francesco; Broggi, Giovanni.

In: Journal of Neuro-Oncology, Vol. 88, No. 1, 05.2008, p. 105-113.

Research output: Contribution to journalArticle

@article{0142def736f4478480a622b76222acf3,
title = "Treatment of recurrent glioblastoma: Can local delivery of mitoxantrone improve survival?",
abstract = "In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1-5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43{\%}, respectively, with a median survival time (mST) of 5 months (range 4-6) and 25{\%} of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1{\%}, respectively, with a mST of 8 months (range 6-10) and 25{\%} of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7{\%}, respectively, with a mST of 11 months (range 9-13) and 25{\%} of pts alive at 18 months (A vs. B vs. C, log-rank P <0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36{\%} the risk of death (HR = 0.64; 0.460-0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50{\%} (HR = 0.50; 0.38-0.68).",
keywords = "Glioblastoma, Locoregional chemotherapy, Mitoxantrone, Ommaya reservoir, Rickam reservoir",
author = "Amerigo Boiardi and Antonio Silvani and Marica Eoli and Elena Lamperti and Andrea Salmaggi and Paola Gaviani and Anna Fiumani and Andrea Botturi and Chiara Falcone and Alessandra Solari and Graziella Filippini and Francesco Meco and Giovanni Broggi",
year = "2008",
month = "5",
doi = "10.1007/s11060-008-9540-6",
language = "English",
volume = "88",
pages = "105--113",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Treatment of recurrent glioblastoma

T2 - Can local delivery of mitoxantrone improve survival?

AU - Boiardi, Amerigo

AU - Silvani, Antonio

AU - Eoli, Marica

AU - Lamperti, Elena

AU - Salmaggi, Andrea

AU - Gaviani, Paola

AU - Fiumani, Anna

AU - Botturi, Andrea

AU - Falcone, Chiara

AU - Solari, Alessandra

AU - Filippini, Graziella

AU - Meco, Francesco

AU - Broggi, Giovanni

PY - 2008/5

Y1 - 2008/5

N2 - In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1-5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43%, respectively, with a median survival time (mST) of 5 months (range 4-6) and 25% of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1%, respectively, with a mST of 8 months (range 6-10) and 25% of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7%, respectively, with a mST of 11 months (range 9-13) and 25% of pts alive at 18 months (A vs. B vs. C, log-rank P <0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36% the risk of death (HR = 0.64; 0.460-0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50% (HR = 0.50; 0.38-0.68).

AB - In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1-5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43%, respectively, with a median survival time (mST) of 5 months (range 4-6) and 25% of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1%, respectively, with a mST of 8 months (range 6-10) and 25% of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7%, respectively, with a mST of 11 months (range 9-13) and 25% of pts alive at 18 months (A vs. B vs. C, log-rank P <0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36% the risk of death (HR = 0.64; 0.460-0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50% (HR = 0.50; 0.38-0.68).

KW - Glioblastoma

KW - Locoregional chemotherapy

KW - Mitoxantrone

KW - Ommaya reservoir

KW - Rickam reservoir

UR - http://www.scopus.com/inward/record.url?scp=42349107740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349107740&partnerID=8YFLogxK

U2 - 10.1007/s11060-008-9540-6

DO - 10.1007/s11060-008-9540-6

M3 - Article

C2 - 18283418

AN - SCOPUS:42349107740

VL - 88

SP - 105

EP - 113

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -